A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
Phase 1
Recruiting
- Conditions
- Oncology
- Registration Number
- 2023-506539-14-00
- Lead Sponsor
- Systimmune Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised, recruiting
- Sex
- Not specified
- Target Recruitment
- 54
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (13)
Institut Gustave Roussy
🇫🇷Villejuif, France
Assistance Publique Hopitaux De Paris
🇫🇷Paris, France
Centre Leon Berard
🇫🇷Lyon, France
Institut De Cancerologie De L Ouest
🇫🇷St Herblain, France
Hospital Universitario 12 De Octubre
🇪🇸Madrid, Spain
Hospital De La Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Hospital Beata Maria Ana
🇪🇸Madrid, Spain
Hospital Universitario Hm Sanchinarro
🇪🇸Madrid, Spain
Hospital Universitario Virgen De La Macarena
🇪🇸Sevilla, Spain
Hospital Universitari Vall D Hebron
🇪🇸Barcelona, Spain
Scroll for more (3 remaining)Institut Gustave Roussy🇫🇷Villejuif, FranceAnas GazzahSite contact+33142115667Anas.gazzah@gustaveroussy.fr